Sirolimus Associated Pericarditis

Kandalaft, Osama; Samanani, Shazia; Aftab, Hassaan

doi:10.1016/s0735-1097(18)32981-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature on pericardial effusion in sirolimus-treated renal transplant patients remains limited. While sirolimus-treated cardiac transplant patients have a reported incidence of pericardial effusion of 9%-30%, the largest single center report of pericardial effusion in renal transplant patients noted only 19 of 792 cases studied were affected [4,5]. In these patients, the mean duration of sirolimus treatment prior to symptoms was quite long at 5.06 years (ranging from 0.5-9.8), consistent with our patient's late presentation, approximately nine years after starting sirolimus.…”

Section: Discussionmentioning

confidence: 99%

Hemopericardium in a Sirolimus-Treated Renal Transplant Patient

Groudan

Sawalha

Bhat

et al. 2020

Cureus

View full text Add to dashboard Cite

Sirolimus is an immunosuppressant frequently prescribed to prevent graft-vs-host disease in renal transplant patients. Pericardial effusion is recognized as a rare and potentially lethal side effect of this medication. Hemopericardium, specifically, is an even rarer complication that has yet to be reported in the literature. We report the first case of sirolimus-induced hemopericardium in a renal transplant patient.

show abstract

Section: Discussionmentioning

confidence: 99%